Molecular targeted therapies in advanced or metastatic chordoma patients: Facts and hypotheses

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 1, 2015, Pages 125-131

  Lebellec, Loïc ^a   Aubert, Sébastien ^b   Zaïri, Fahed ^b   Ryckewaert, Thomas ^a   Chauffert, Bruno ^c   Penel, Nicolas ^a,d  

^a CENTRE OSCAR LAMBRET   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d UNIV LILLE   (France)

Author keywords

Chordomas; Imatinib; Molecular targeted therapies; Review

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAPAMYCIN; SORAFENIB; STEM CELL FACTOR; THALIDOMIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN A;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; CHORDOMA; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION; BONE; BONE NEOPLASMS; DRUG EFFECTS; METABOLISM; NEOPLASM METASTASIS; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE NEOPLASMS; CHORDOMA; HUMANS; IMATINIB MESYLATE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84930817939     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.01.010     Document Type: Review

References (33)

1. Walcott B.P., Nahed B.V., Mohyeldin A., Coumans J.V., Kahle K.T., Ferreira M.J. Chordoma: current concepts, management and future directions. Lancet Oncol 2012, 13:e69-e76.
2. Vieira de Castro C., Guimaraes G., Aguiar S., et al. Tyrosine kinase receptor expression in chordomas: phosphorlyated AKT correlates inversely with outcome. Hum Pathol 2013, 44:1747-1755.
3. Tamborini E., Miselli F., Negri T., et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA and KIT receptors in chordomas. Clin Cancer Res 2006, 12:6920-6928.
4. Crockard H.A., Steel T., Plowman N., et al. A multidisciplinary team approach to skull base chordomas. J Neurosurg 2001, 95:175-183.
5. Stacchiotti S., Casali P.G., Lo Vullo S., et al. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 2010, 17:211-219.
6. Uhl M., Edler L., Jensen A.D., Habl G., et al. Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol. Radiat Oncol 2014, 9:100.
7. Stacchiotti S., Marrari A., Tamborini E., et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 2009, 20:1886-1894.
8. Casali P.G., Massina A., Stacchiotti S., et al. Imatinib mesylate in chordoma. Cancer 2004, 101:2086-2097.
9. Launay S.G., Chetaille B., Medina F., et al. Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review. BMC Cancer 2011, 11:423.
10. Singhal N., Kotasek D., Parnis F.X. Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs 2009, 20:953-955.
11. Mercier F., Guiot M.C., Bojanowski M.W. Treatment of chordoma with imatinib complicated by intracranial hemorrhage: a case showing dissociation between biological effect and therapeutic outcome. J Neurooncol 2012, 107:435-437.
12. Chay W.Y., Teo M., Sittampalam K., et al. Effective use of thalidomide in the treatment of recurrent metastatic chordoma. J Clin Oncol 2011, 29:e477-e480.
13. Lindén O., Stenberg L., Kjellén E. Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib. Acta Oncol 2009, 48:158-159.
14. Hof H., Welzel T., Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 2006, 29:572-574.
15. Asklund T., Sandström M., Shahidi S., Riklund K., Henriksson R. Durable stabilization of three chordoma cases by bevacizumab and erlotinib. Acta Oncol 2014, 53(7):980-984.
16. Svoboda R.M., Mackay D., Welsch M.J., et al. Multiple cutaneous metastatic chordomas from the sacrum. J Am Acad Dermatol 2012, e246.
17. Heinrich M.C., Joensuu H., Demetri G.D., et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008, 14:2717-2725.
18. Geoerger B., Morlandb B., Ndiayec A., et al. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. Eur J Cancer 2009, 45:2342-2351.
19. George S., Merriam P., Maki R.G., et al. Multicenter phase II trial of sunitinib in the treatment of non-gastrointestinal stromal tumor sarcomas. J Clin Oncol 2009, 27:3154-3160.
20. Adenis A., Ray-Coquard I., Italiano A., et al. A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. Br J Cancer 2013, 109:2574-2578.
21. Stacchiotti S., Longhi A., Ferraresi V., et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol 2012, 30:914-920.
22. Stacchiotti S., Tamborini E., Lo Vullo S., et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol 2013, 24:1931-1936.
23. Orzan F., Terreni M.R., Longoni M., et al. Expression study of the target receptor tyrosine kinase of imatinib mesylate in skull base chordomas. Oncol Rep 2007, 18:249-252.
24. Weinberger P.M., Yu Z., Kowalski D., et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 2005, 131:707-711.
25. Shalaby A., Presneau N., Ye H., et al. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol 2011, 223:336-346.
26. Li X., Ji Z., Ma Y., Qiu X., Fan Q., Ma B. Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomas. Oncol Lett 2012, 3:1268-1274.
27. Chen K.W., Yang H.L., Lu J., et al. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J Neurooncol 2011, 101:357-363.
28. Naka T., Boltze C., Samii A., et al. Expression of c-MET, low molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. Histopathology 2009, 54:607-613.
29. Presneau N., Shalaby A., Idowu B., et al. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer 2009, 100:1406-1414.
30. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M. Oxford Centre for Evidence-Based Medicine Levels of Evidence. 2001. Available at: www.cebm.net/levels_of_evidence.asp#levels. (accessed February 04th, 2015).
31. Freidlin B., Simon R. Evaluation of randomized discontinuation design. J Clin Oncol 2005, 23:5094-5098.
32. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-206.
33. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.